AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
22 Setembro 2023 - 10:05AM
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or
the “Company”) today announced Chris McAleer, Ph.D., Scientific
Officer of AIM will present at the 3rd Annual Marie
Sklodowska-Curie Symposium on Cancer Research and Care being held
at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y.,
September 20-22, 2023. In addition to the presentation, the Company
is proud to announce its sponsorship of the event.
Details for the presentation are as follows:
Title: Rintatolimod
(Ampligen®): Overview of Ampligen’s Clinical Progress in
OncologyPresenter: Christopher McAleer,
Ph.D.Session: Session 7: Team Science: National
and International Collaborations with NGOs, Academia, Pharma, &
BiotechDate: Friday, September 22, 2023
For more information about the conference,
visit: https://www.roswellpark.org/msc-symposium.
The presentation will be available on the AIM
website once presented at the conference.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024